National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lesinurad (Zurampic®)

Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.

NCPE Assessment Process Ongoing
Rapid review received 15/03/2017
Rapid review completed 20/03/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 29/03/2017
Pre-submission consultation with Applicant 22/05/2017
Submission received from Applicant 07/06/2018
Preliminary review sent to Applicant 18/07/2018
NCPE assessment re-commenced 15/08/2018
Factual accuracy sent to Applicant 15/11/2018
NCPE assessment re-commenced 21/11/2018
NCPE Assessment Complete 06/12/2018
NCPE assessment outcome The NCPE recommends that lesinurad not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.